Wednesday - March 18, 2026
FDA Center for Drug Evaluation & Research Issues Warning Letter to Novo Nordisk
March 11, 2026
WASHINGTON, March 11 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Novo Nordisk Inc. from its Center for Drug Evaluation and Research:

* * *

Recipient: Mr. David S. Moore, President, Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, United States

Issuing Office: Center for Drug Evaluation and Research (CDER), United States

Dear Mr. Moore:

This . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products